What is Nelfinavir (Viracept)?
Nelfinavir is a type of protease inhibitor. Nelfinavir belongs to category of retroviral protease inhibitor drugs.
It is an inhibitor of the human immunodeficiency virus (HIV) protease. Inhibition of the viral protease prevents cleavage of the gag pol poly-protein resulting in the production of immature, non infectious virus. Nelfinavir is an anti retro viral drug used in the treatment of the human immunodeficiency virus (HIV). Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is generally used in combination with other antiretroviral drugs. This drug is commonly sold as Brand Name Viracept.
Indication/Contraindication for use of Nelfinavir (Viracept)
- It is contraindicated in patients with clinically significant hypersensitivity to any of its components.
- It is indicated for the treatment of HIV infection when antiretroviral therapy is warranted.
Side Effects of Nelfinavir (Viracept)
Back pain, fever, headache, anorexia, dyspepsia, gastrointestinal bleeding, hepatitis, anemia, leukemic and thrombotic, anxiety, depression, dizziness, sleep disorder, suicide ideation, dyspeptic, pharyngitis, rhinitis, dermatitis, eye disorder, sexual dysfunction and urine abnormality.
Dosage and Prescribing Information for Nelfinavir (Viracept)
Adults : The recommended dose is 750 mg (three 250 mg tablets) three times daily. Nelfinavir methylated should be taken with a meal or light snack. Pediatric : The recommended oral dose of nelfinavir mesylate for pediatric patients 2 to 13 years of age is 20-30 mg/kg per dose, three times daily with a meal or a light snack.
Drug Interactions of Nelfinavir (Viracept)
The drugs which should not be co administered with Nelfinavir Mesylate are Amiodarone, quinidine, astemizole, terfenadine, ergot derivatives, rifampin, midazole, triazolam, cisapride.
Precautions while prescribing Nelfinavir (Viracept)
- Nelfinavir is principally metabolized by the liver.
- Therefore, caution should be exercised when administering this drug to patients with hepatic impairment.
- Lactation: It is not known whether nelfinavir is excreted in human milk.